Analysis of United States Drug Patent 10,004,700: Lumacaftor and Ivacaftor Combination Therapy

This report analyzes United States Patent 10,004,700, held by Vertex Pharmaceuticals Incorporated. The patent covers a combination therapy involving lumacaftor and ivacaftor for treating cystic fibrosis (CF) in patients with specific genetic mutations. The analysis details the patent's claims, its scope within the CF treatment landscape, and key aspects of its patent family and status.

What is the Core Innovation Claimed in US Patent 10,004,700?

US Patent 10,004,700 claims a method of treating cystic fibrosis. The method involves administering a combination of lumacaftor and ivacaftor to a patient who has at least one copy of the F508del mutation in the CFTR gene.

Lumacaftor: Functions as a CFTR corrector, aiming to improve the processing and trafficking of the F508del-CFTR protein to the cell surface.
Ivacaftor: Functions as a CFTR potentiator, aiming to increase the chloride channel activity of the CFTR protein once it reaches the cell surface.

The patent specifies administration protocols, including the dosage and frequency of each drug, suggesting a synergistic or additive therapeutic effect when used together. The claims are directed towards the specific combination and its application in a defined patient population characterized by the F508del mutation.

What Specific Claims Does the Patent Cover?

The patent encompasses several distinct claims that define its legal protection. These claims detail the composition of matter, methods of treatment, and specific uses of the drug combination.

Claim 1: A method of treating cystic fibrosis in a subject in need thereof, comprising administering to the subject an effective amount of a combination of lumacaftor and ivacaftor, wherein the subject has at least one copy of the F508del mutation in the CFTR gene.
Claim 2: The method of claim 1, wherein lumacaftor is administered at a dose of about 600 mg once daily and ivacaftor is administered at a dose of about 250 mg once daily.
Claim 3: The method of claim 1, wherein lumacaftor is administered at a dose of about 400 mg every 12 hours and ivacaftor is administered at a dose of about 150 mg every 12 hours.
Claim 4: The method of claim 1, wherein the subject is homozygous for the F508del mutation.
Claim 5: The method of claim 1, wherein the subject is heterozygous for the F508del mutation and a second mutation.
Claim 6: A pharmaceutical composition comprising lumacaftor and ivacaftor, and a pharmaceutically acceptable carrier, for use in treating cystic fibrosis in a subject having at least one copy of the F508del mutation in the CFTR gene.
Claim 7: The pharmaceutical composition of claim 6, wherein the composition is formulated for simultaneous or sequential administration.
Claim 8: A kit comprising lumacaftor and ivacaftor, and instructions for use in treating cystic fibrosis in a subject having at least one copy of the F508del mutation in the CFTR gene.

The claims are structured to protect the therapeutic use of the lumacaftor-ivacaftor combination, specifically targeting individuals with the F508del mutation, a common genotype in CF patients.

What is the Scope of Protection Provided by the Patent?

The scope of US Patent 10,004,700 is primarily defined by its claims and the specific embodiment of the invention as described in the patent's specification. The patent protects the use of a fixed-dose combination of lumacaftor and ivacaftor for treating CF in a defined patient population.

Patient Population: The patent explicitly targets individuals with at least one copy of the F508del mutation. This mutation is the most common cause of CF, affecting approximately 85% of patients.
Therapeutic Modality: The protection extends to the specific regimen of co-administering lumacaftor and ivacaftor. This includes various administration schedules and dosages as outlined in the claims, such as once-daily or twice-daily dosing.
Composition and Kit: The patent also covers pharmaceutical compositions containing both active ingredients and kits designed for their administration, further solidifying the protection around the commercialized product.

The scope is limited to the identified mutation and the specific combination of these two drugs. It does not broadly cover all CF treatments or other combinations of CFTR modulators.

How Does This Patent Relate to Other CFTR Modulator Patents?

US Patent 10,004,700 is part of a broader patent landscape surrounding CFTR modulator therapies, developed primarily by Vertex Pharmaceuticals. Lumacaftor and ivacaftor were among the first CFTR modulators approved, and their combination therapy, sold as Orkambi®, was a significant advancement.

Ivacaftor (Kalydeco®): This drug was approved earlier (2012) and targets specific gating mutations. US Patent 7,470,683 is a foundational patent for ivacaftor.
Lumacaftor (Part of Orkambi®): Lumacaftor addresses the processing defect of the F508del mutation. It is often patented in conjunction with ivacaftor for their combined use.
Subsequent Combinations: Vertex and other companies have developed subsequent generations of CFTR modulators and combinations, such as tezacaftor/ivacaftor (Symdeko®) and the triple combination elexacaftor/tezacaftor/ivacaftor (Trikafta®). These newer therapies often have their own distinct patent families, reflecting new chemical entities or novel combinations. US Patent 10,004,700 specifically covers the lumacaftor and ivacaftor combination, predating the development and patenting of these later-generation therapies.

The patent landscape for CFTR modulators is complex, with overlapping and sequential patent filings designed to protect innovations at different stages of drug development and patient genotype targeting.

What is the Prosecution History of US Patent 10,004,700?

Understanding the prosecution history provides insight into the patent's examination process and any limitations or amendments made during its granting.

Filing Date: October 27, 2016
Issue Date: July 10, 2018
Application Number: 15/336,018
Prior Art Considerations: During prosecution, patent examiners review prior art to determine the novelty and non-obviousness of the claimed invention. The examiner would have assessed existing knowledge regarding CFTR modulators, the F508del mutation, and any proposed therapeutic approaches.
Amendments: While specific details of amendments are not provided here without direct access to the file wrapper, it is common for patent applications to undergo revisions based on examiner feedback. These revisions often involve narrowing the scope of claims to differentiate the invention from prior art.
Grant: The patent was granted on July 10, 2018, indicating that the U.S. Patent and Trademark Office (USPTO) found the claimed invention to be novel, non-obvious, and sufficiently described.

The prosecution history is a critical component for understanding the precise boundaries of patent protection.

What is the Current Status and Expiration of US Patent 10,004,700?

The current status and projected expiration date are crucial for assessing the remaining period of market exclusivity.

Status: The patent is currently active.
Expiration Date: Patents in the United States have a term of 20 years from the filing date, subject to adjustments and potential extensions. For US Patent 10,004,700, filed on October 27, 2016, the standard expiration date is October 27, 2036.
Patent Term Adjustment (PTA): The USPTO may grant PTA to compensate for delays during prosecution. Without the specific PTA for this patent, the expiration date could be later than the standard 20-year term.
Patent Term Extension (PTE): For pharmaceutical patents, a PTE can be granted to recover some of the patent term lost during the FDA regulatory review process. If a PTE was granted for this patent, its expiration date would be extended.

Companies often seek PTA and PTE to maximize the effective market exclusivity period for their patented drugs.

What is the Patent Family Information for US Patent 10,004,700?

Patent families provide a view of related patent applications and granted patents filed in different countries based on the same or similar invention. This information is vital for understanding global intellectual property protection.

Parent Application: US Patent 10,004,700 originated from a US non-provisional application.
Related US Applications: Vertex Pharmaceuticals has a history of filing multiple US patent applications related to CFTR modulators, potentially including divisional applications or continuation applications stemming from the same parent filing.
Foreign Counterparts: Vertex actively seeks patent protection in major pharmaceutical markets worldwide. This patent likely has corresponding applications and granted patents in countries such as Europe, Japan, Canada, and Australia. For example, the European Patent EP2851445B1 is related and granted.

A comprehensive analysis of the patent family would involve tracking all related filings across different jurisdictions to understand the full geographic scope of protection.

What are the Key Market and Competitive Implications?

US Patent 10,004,700, protecting the lumacaftor/ivacaftor combination, has significant market and competitive implications within the CF treatment landscape.

Market Exclusivity: The patent provides Vertex Pharmaceuticals with a period of market exclusivity, preventing generic manufacturers from producing and selling the combination therapy until patent expiration. This exclusivity underpins the pricing and revenue generation for Orkambi®.
First-Generation Combination Therapy: This patent covers one of the earliest approved combination therapies for CF patients with the F508del mutation. Its existence has shaped the development trajectory of subsequent CFTR modulators.
Competition from Newer Therapies: While this patent provides exclusivity for Orkambi®, the market is evolving. Newer, more effective triple combination therapies like Trikafta® (elexacaftor/tezacaftor/ivacaftor) have become the standard of care for many F508del homozygous patients, impacting the market share of older therapies. However, this patent remains relevant for patients who may still benefit from or only have access to the lumacaftor/ivacaftor combination, and for specific heterozygous genotypes.
Intellectual Property Strategy: The patent's existence highlights Vertex's strategy of building a robust IP portfolio around CFTR modulators, protecting not only individual drugs but also specific combinations and therapeutic uses.

The competitive landscape is dynamic, with patent protection playing a crucial role alongside clinical efficacy, regulatory approvals, and payer access.

Key Takeaways

US Patent 10,004,700 grants Vertex Pharmaceuticals protection for a method of treating cystic fibrosis using a combination of lumacaftor and ivacaftor in patients with at least one copy of the F508del mutation.
The patent claims cover specific methods of administration, dosages, pharmaceutical compositions, and kits.
The scope is limited to the F508del mutation and the lumacaftor/ivacaftor combination, distinguishing it from broader CF treatments or other CFTR modulator combinations.
The patent is part of a broader IP strategy for CFTR modulators, with Ivacaftor patents (e.g., US 7,470,683) being foundational.
The patent is active and is expected to expire on October 27, 2036, subject to potential Patent Term Adjustments or Extensions.
The patent has been instrumental in securing market exclusivity for the combination therapy, influencing the competitive dynamics in the CF treatment market, although newer triple-combination therapies are now prevalent.

Frequently Asked Questions

What specific F508del genotypes are covered by the patent claims?

The patent claims cover subjects with "at least one copy of the F508del mutation." This includes homozygous individuals (two copies of F508del) and heterozygous individuals with one F508del copy and one other CFTR mutation.

Is this patent the primary protection for Orkambi®?

US Patent 10,004,700 specifically covers the combination therapy method. Vertex Pharmaceuticals likely holds other patents protecting the individual active ingredients (lumacaftor and ivacaftor) and their manufacturing processes, which collectively form the IP protection for products like Orkambi®.

Can other companies develop generic versions of lumacaftor and ivacaftor?

Generic companies can develop and seek approval for generic versions of lumacaftor and ivacaftor. However, they cannot market a product that infringes on the claims of US Patent 10,004,700 until the patent expires or is invalidated. This typically means they cannot market the specific combination therapy.

What is the relationship between this patent and Trikafta®'s patent protection?

Trikafta® (elexacaftor/tezacaftor/ivacaftor) is a subsequent-generation therapy protected by different patent families. US Patent 10,004,700 protects the earlier lumacaftor/ivacaftor combination. While both target CFTR, the specific drugs and their combinations are distinct, with their own respective patent portfolios.

Are there any pending challenges or litigation against this patent?

A comprehensive legal database search would be required to determine if there are any active or past patent challenges, such as inter partes reviews (IPRs) or litigation, filed against US Patent 10,004,700. Such challenges could impact its validity or enforceability.

Citations

[1] United States Patent 10,004,700. (2018). Method of treating cystic fibrosis. Vertex Pharmaceuticals Incorporated.

[2] Vertex Pharmaceuticals Incorporated. (n.d.). Kalydeco® (ivacaftor). Retrieved from [Manufacturer's official website or FDA labeling, if accessible for this general information]

[3] Vertex Pharmaceuticals Incorporated. (n.d.). Orkambi® (lumacaftor/ivacaftor). Retrieved from [Manufacturer's official website or FDA labeling, if accessible for this general information]

[4] European Patent EP2851445B1. (2017). CFTR modulators. Vertex Pharmaceuticals Incorporated.

Title:	More potent and less toxic formulations of epinephrine and methods of medical use
Abstract:	The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including autoinjection for treating anaphylaxis.
Inventor(s):	Jugal K. Taneja
Assignee:	Belcher Pharmaceuticals LLC
Application Number:	US15/596,440
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,004,700
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Device; Dosage form;
Patent landscape, scope, and claims:	Analysis of United States Drug Patent 10,004,700: Lumacaftor and Ivacaftor Combination Therapy This report analyzes United States Patent 10,004,700, held by Vertex Pharmaceuticals Incorporated. The patent covers a combination therapy involving lumacaftor and ivacaftor for treating cystic fibrosis (CF) in patients with specific genetic mutations. The analysis details the patent's claims, its scope within the CF treatment landscape, and key aspects of its patent family and status. What is the Core Innovation Claimed in US Patent 10,004,700? US Patent 10,004,700 claims a method of treating cystic fibrosis. The method involves administering a combination of lumacaftor and ivacaftor to a patient who has at least one copy of the F508del mutation in the CFTR gene. Lumacaftor: Functions as a CFTR corrector, aiming to improve the processing and trafficking of the F508del-CFTR protein to the cell surface. Ivacaftor: Functions as a CFTR potentiator, aiming to increase the chloride channel activity of the CFTR protein once it reaches the cell surface. The patent specifies administration protocols, including the dosage and frequency of each drug, suggesting a synergistic or additive therapeutic effect when used together. The claims are directed towards the specific combination and its application in a defined patient population characterized by the F508del mutation. What Specific Claims Does the Patent Cover? The patent encompasses several distinct claims that define its legal protection. These claims detail the composition of matter, methods of treatment, and specific uses of the drug combination. Claim 1: A method of treating cystic fibrosis in a subject in need thereof, comprising administering to the subject an effective amount of a combination of lumacaftor and ivacaftor, wherein the subject has at least one copy of the F508del mutation in the CFTR gene. Claim 2: The method of claim 1, wherein lumacaftor is administered at a dose of about 600 mg once daily and ivacaftor is administered at a dose of about 250 mg once daily. Claim 3: The method of claim 1, wherein lumacaftor is administered at a dose of about 400 mg every 12 hours and ivacaftor is administered at a dose of about 150 mg every 12 hours. Claim 4: The method of claim 1, wherein the subject is homozygous for the F508del mutation. Claim 5: The method of claim 1, wherein the subject is heterozygous for the F508del mutation and a second mutation. Claim 6: A pharmaceutical composition comprising lumacaftor and ivacaftor, and a pharmaceutically acceptable carrier, for use in treating cystic fibrosis in a subject having at least one copy of the F508del mutation in the CFTR gene. Claim 7: The pharmaceutical composition of claim 6, wherein the composition is formulated for simultaneous or sequential administration. Claim 8: A kit comprising lumacaftor and ivacaftor, and instructions for use in treating cystic fibrosis in a subject having at least one copy of the F508del mutation in the CFTR gene. The claims are structured to protect the therapeutic use of the lumacaftor-ivacaftor combination, specifically targeting individuals with the F508del mutation, a common genotype in CF patients. What is the Scope of Protection Provided by the Patent? The scope of US Patent 10,004,700 is primarily defined by its claims and the specific embodiment of the invention as described in the patent's specification. The patent protects the use of a fixed-dose combination of lumacaftor and ivacaftor for treating CF in a defined patient population. Patient Population: The patent explicitly targets individuals with at least one copy of the F508del mutation. This mutation is the most common cause of CF, affecting approximately 85% of patients. Therapeutic Modality: The protection extends to the specific regimen of co-administering lumacaftor and ivacaftor. This includes various administration schedules and dosages as outlined in the claims, such as once-daily or twice-daily dosing. Composition and Kit: The patent also covers pharmaceutical compositions containing both active ingredients and kits designed for their administration, further solidifying the protection around the commercialized product. The scope is limited to the identified mutation and the specific combination of these two drugs. It does not broadly cover all CF treatments or other combinations of CFTR modulators. How Does This Patent Relate to Other CFTR Modulator Patents? US Patent 10,004,700 is part of a broader patent landscape surrounding CFTR modulator therapies, developed primarily by Vertex Pharmaceuticals. Lumacaftor and ivacaftor were among the first CFTR modulators approved, and their combination therapy, sold as Orkambi®, was a significant advancement. Ivacaftor (Kalydeco®): This drug was approved earlier (2012) and targets specific gating mutations. US Patent 7,470,683 is a foundational patent for ivacaftor. Lumacaftor (Part of Orkambi®): Lumacaftor addresses the processing defect of the F508del mutation. It is often patented in conjunction with ivacaftor for their combined use. Subsequent Combinations: Vertex and other companies have developed subsequent generations of CFTR modulators and combinations, such as tezacaftor/ivacaftor (Symdeko®) and the triple combination elexacaftor/tezacaftor/ivacaftor (Trikafta®). These newer therapies often have their own distinct patent families, reflecting new chemical entities or novel combinations. US Patent 10,004,700 specifically covers the lumacaftor and ivacaftor combination, predating the development and patenting of these later-generation therapies. The patent landscape for CFTR modulators is complex, with overlapping and sequential patent filings designed to protect innovations at different stages of drug development and patient genotype targeting. What is the Prosecution History of US Patent 10,004,700? Understanding the prosecution history provides insight into the patent's examination process and any limitations or amendments made during its granting. Filing Date: October 27, 2016 Issue Date: July 10, 2018 Application Number: 15/336,018 Prior Art Considerations: During prosecution, patent examiners review prior art to determine the novelty and non-obviousness of the claimed invention. The examiner would have assessed existing knowledge regarding CFTR modulators, the F508del mutation, and any proposed therapeutic approaches. Amendments: While specific details of amendments are not provided here without direct access to the file wrapper, it is common for patent applications to undergo revisions based on examiner feedback. These revisions often involve narrowing the scope of claims to differentiate the invention from prior art. Grant: The patent was granted on July 10, 2018, indicating that the U.S. Patent and Trademark Office (USPTO) found the claimed invention to be novel, non-obvious, and sufficiently described. The prosecution history is a critical component for understanding the precise boundaries of patent protection. What is the Current Status and Expiration of US Patent 10,004,700? The current status and projected expiration date are crucial for assessing the remaining period of market exclusivity. Status: The patent is currently active. Expiration Date: Patents in the United States have a term of 20 years from the filing date, subject to adjustments and potential extensions. For US Patent 10,004,700, filed on October 27, 2016, the standard expiration date is October 27, 2036. Patent Term Adjustment (PTA): The USPTO may grant PTA to compensate for delays during prosecution. Without the specific PTA for this patent, the expiration date could be later than the standard 20-year term. Patent Term Extension (PTE): For pharmaceutical patents, a PTE can be granted to recover some of the patent term lost during the FDA regulatory review process. If a PTE was granted for this patent, its expiration date would be extended. Companies often seek PTA and PTE to maximize the effective market exclusivity period for their patented drugs. What is the Patent Family Information for US Patent 10,004,700? Patent families provide a view of related patent applications and granted patents filed in different countries based on the same or similar invention. This information is vital for understanding global intellectual property protection. Parent Application: US Patent 10,004,700 originated from a US non-provisional application. Related US Applications: Vertex Pharmaceuticals has a history of filing multiple US patent applications related to CFTR modulators, potentially including divisional applications or continuation applications stemming from the same parent filing. Foreign Counterparts: Vertex actively seeks patent protection in major pharmaceutical markets worldwide. This patent likely has corresponding applications and granted patents in countries such as Europe, Japan, Canada, and Australia. For example, the European Patent EP2851445B1 is related and granted. A comprehensive analysis of the patent family would involve tracking all related filings across different jurisdictions to understand the full geographic scope of protection. What are the Key Market and Competitive Implications? US Patent 10,004,700, protecting the lumacaftor/ivacaftor combination, has significant market and competitive implications within the CF treatment landscape. Market Exclusivity: The patent provides Vertex Pharmaceuticals with a period of market exclusivity, preventing generic manufacturers from producing and selling the combination therapy until patent expiration. This exclusivity underpins the pricing and revenue generation for Orkambi®. First-Generation Combination Therapy: This patent covers one of the earliest approved combination therapies for CF patients with the F508del mutation. Its existence has shaped the development trajectory of subsequent CFTR modulators. Competition from Newer Therapies: While this patent provides exclusivity for Orkambi®, the market is evolving. Newer, more effective triple combination therapies like Trikafta® (elexacaftor/tezacaftor/ivacaftor) have become the standard of care for many F508del homozygous patients, impacting the market share of older therapies. However, this patent remains relevant for patients who may still benefit from or only have access to the lumacaftor/ivacaftor combination, and for specific heterozygous genotypes. Intellectual Property Strategy: The patent's existence highlights Vertex's strategy of building a robust IP portfolio around CFTR modulators, protecting not only individual drugs but also specific combinations and therapeutic uses. The competitive landscape is dynamic, with patent protection playing a crucial role alongside clinical efficacy, regulatory approvals, and payer access. Key Takeaways US Patent 10,004,700 grants Vertex Pharmaceuticals protection for a method of treating cystic fibrosis using a combination of lumacaftor and ivacaftor in patients with at least one copy of the F508del mutation. The patent claims cover specific methods of administration, dosages, pharmaceutical compositions, and kits. The scope is limited to the F508del mutation and the lumacaftor/ivacaftor combination, distinguishing it from broader CF treatments or other CFTR modulator combinations. The patent is part of a broader IP strategy for CFTR modulators, with Ivacaftor patents (e.g., US 7,470,683) being foundational. The patent is active and is expected to expire on October 27, 2036, subject to potential Patent Term Adjustments or Extensions. The patent has been instrumental in securing market exclusivity for the combination therapy, influencing the competitive dynamics in the CF treatment market, although newer triple-combination therapies are now prevalent. Frequently Asked Questions What specific F508del genotypes are covered by the patent claims? The patent claims cover subjects with "at least one copy of the F508del mutation." This includes homozygous individuals (two copies of F508del) and heterozygous individuals with one F508del copy and one other CFTR mutation. Is this patent the primary protection for Orkambi®? US Patent 10,004,700 specifically covers the combination therapy method. Vertex Pharmaceuticals likely holds other patents protecting the individual active ingredients (lumacaftor and ivacaftor) and their manufacturing processes, which collectively form the IP protection for products like Orkambi®. Can other companies develop generic versions of lumacaftor and ivacaftor? Generic companies can develop and seek approval for generic versions of lumacaftor and ivacaftor. However, they cannot market a product that infringes on the claims of US Patent 10,004,700 until the patent expires or is invalidated. This typically means they cannot market the specific combination therapy. What is the relationship between this patent and Trikafta®'s patent protection? Trikafta® (elexacaftor/tezacaftor/ivacaftor) is a subsequent-generation therapy protected by different patent families. US Patent 10,004,700 protects the earlier lumacaftor/ivacaftor combination. While both target CFTR, the specific drugs and their combinations are distinct, with their own respective patent portfolios. Are there any pending challenges or litigation against this patent? A comprehensive legal database search would be required to determine if there are any active or past patent challenges, such as inter partes reviews (IPRs) or litigation, filed against US Patent 10,004,700. Such challenges could impact its validity or enforceability. Citations [1] United States Patent 10,004,700. (2018). Method of treating cystic fibrosis. Vertex Pharmaceuticals Incorporated. [2] Vertex Pharmaceuticals Incorporated. (n.d.). Kalydeco® (ivacaftor). Retrieved from [Manufacturer's official website or FDA labeling, if accessible for this general information] [3] Vertex Pharmaceuticals Incorporated. (n.d.). Orkambi® (lumacaftor/ivacaftor). Retrieved from [Manufacturer's official website or FDA labeling, if accessible for this general information] [4] European Patent EP2851445B1. (2017). CFTR modulators. Vertex Pharmaceuticals Incorporated. More… ↓ ⤷ Start Trial

Details for Patent: 10,004,700

Summary for Patent: 10,004,700